Search
pertuzumab/trastuzumab with hyaluronidase (Phesgo)
Indications:
- treatment of HER2+ breast cancer
- initially used in combination with chemotherapy
* for use with an FDA-approved companion diagnostic test
Dosage:
- subcutaneous injection
* can be administered at home by a qualified health care professional once chemotherapy regimen has been completed
Adverse effects:
- alopecia, nausea, diarrhea, anemia, asthenia
* boxed warnings
- risk of heart failure, fetal harm & lung toxicity
Drug interactions:
- Phesgocan worsen chemotherapy induced neutropenia
Mechanism of action:
- pertuzumab & trastuzumab bind to sites on HER2 & disrupt signaling
General
antineoplastic combination (combination chemotherapy)
References
- FDA News Release. June 29, 2020
FDA Approves Breast Cancer Treatment That Can Be Administered At Home
By Health Care Professional.
https://www.fda.gov/news-events/press-announcements/fda-approves-breast-cancer-treatment-can-be-administered-home-health-care-professional
Components
pertuzumab (Perjeta)
trastuzumab (Herceptin, Herzuma, CT-P6)